Therapeutic potential of A2 adenosine receptor pharmacological regulators in the treatment of cardiovascular diseases, recent progress, and prospective.
Adenosine A2 Receptor Agonists
/ adverse effects
Adenosine A2 Receptor Antagonists
/ adverse effects
Animals
Cardiovascular Diseases
/ drug therapy
Cardiovascular System
/ drug effects
Humans
Molecular Targeted Therapy
Receptors, Adenosine A2
/ drug effects
Signal Transduction
/ drug effects
Treatment Outcome
A2 adenosine receptor
cardiovascular diseases
pharmacological inhibitors
Journal
Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
11
11
2017
accepted:
10
07
2018
pubmed:
28
8
2018
medline:
18
12
2019
entrez:
28
8
2018
Statut:
ppublish
Résumé
Adenosine and its analogs are of particular interest as potential therapeutic agents for treatment of cardiovascular diseases (CVDs). A2 adenosine receptor subtypes (A2a and A2b) are extensively expressed in cardiovascular system, and modulation of these receptors using A2 adenosine receptor agonists or antagonists regulates heart rate, blood pressure, heart rate variability, and cardiovascular toxicity during both normoxia and hypoxia conditions. Regulation of A2 adenosine receptor signaling via specific and novel pharmacological regulators is a potentially novel therapeutic approach for a better understanding and hence a better management of CVDs. This review summarizes the role of pharmacological A2 adenosine receptor regulators in the pathogenesis of CVDs.
Substances chimiques
Adenosine A2 Receptor Agonists
0
Adenosine A2 Receptor Antagonists
0
Receptors, Adenosine A2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1295-1299Informations de copyright
© 2018 Wiley Periodicals, Inc.